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Epidemiologic studies in India show that the prevalence of
asthma is increasing, but no genetic studies have been reported
on the Indian population thus far. We selected the IFNG locus
on 12q21 as a candidate gene for asthma on the basis of its role
in pathophysiology and positive linkage demonstrated in other
populations. The aim of this study was to investigate associa-
tion of a CA-repeat marker in this gene with asthma and total
serum IgE levels in the North Indian population. The repeat
region was PCR-amplified from patients and control subjects
and analyzed through use of GeneScan. The distributions of
allele sizes were found to be significantly different between
patients and control subjects (Kolmogorov-Smirnov test, P <
10–6). Alleles 10 and 11 were found to be overrepresented in
individuals with asthma, whereas alleles 13 and 15 were less
likely in asthmatic individuals. We found that the CA-repeat
polymorphism in the IFNG gene was significantly associated
with total serum IgE levels (ANOVA, P < 10–4 for control sub-
jects and P = .0036 for patients). Furthermore, a previously
reported promoter polymorphism at the –333 base pair posi-
tion was not detected in our population. This is the first report
on the association of a candidate gene with asthma from the
Indian subcontinent. (J Allergy Clin Immunol 2002;110:410-2.)
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Recent epidemiologic studies in India have indicated a
rapid rise in the prevalence of asthma (11% to 12%), 34%
of work days being lost.1 Atopic asthma is a complex air-
way disorder in which a number of genetic and environ-
mental factors contribute to disease progression.2 IL-4
plays a central role in the initiation of atopic disorders. In
contrast, IFN-γ inhibits IL-4 function, thereby negatively
regulating this process.3
Earlier genetic studies showed linkage of asthma with
2 markers—D12S351 and D12S390—flanking the IFNG
gene and a CA-repeat in the first intron of IFNG4; a C/T
transition (at the –333 base pair [bp] position) was
detected.5 However, no attempts were made to correlate
these polymorphisms with asthma in the Indian popula-
tion.
In this report, we explore the existence of the promot-
er (–333 bp) polymorphism and the association of the
CA-repeat polymorphism with asthma. We used a case
control study.
METHODS
Patients with asthma (103 unrelated individuals with a mean age
of 29.57 ± 12 years) were diagnosed according to American Tho-
racic Society guidelines; those with self-reported histories of
breathlessness, wheezing, and other allergy symptoms and positive
family histories of atopy and asthma were recruited into the study.
Asthma phenotype was established by pulmonary function testing
(FEV1, reversibility ≥15% increase in FEV1 or forced vital capaci-
ty) through use of a β2-agonist. Ninety unrelated control subjects
with no reported histories of allergic disease or asthma were recruit-
ed. All individuals with parasitic infestations or histories of smok-
ing were excluded.
The geographic region of origin (Northern India) and the migra-
tion status of each patient and each unrelated control were record-
ed. Approval of the ethics committees of the participating centers
and written informed consent from all individuals were obtained.
Total serum IgE (TsIgE) was measured (IgE Quantitation Kit,
Bethyl Laboratories, Inc) and analyzed (SOFT MAX PRO, Molec-
ular Devices). The IFNG promoter fragment (408 bp) was PCR-
amplified from whole blood genomic DNA through use of primers
5′-CGTTTTTCACTTGTTCCCAACCA-3′ and 5′-GATCTTCA-
GATGATCAGAACAAT-3′ (accession number AF375790) and then
Brief communication
Association of IFNG gene polymorphism
with asthma in the Indian population
Rana Nagarkatti, MSc,a Chandrika B. Rao, PhD,a Jai Prakash Rishi, MD,b
Rajesh Chetiwal, MD,b Vipul Shandilya, MBBS,a Vannankandi Vijayan, MD,c
Raj Kumar, MD,c Harish K. Pemde, MD,d Surendra K. Sharma, MD,e
Sweety Sharma, MSc,a Anand B. Singh, PhD,a Sharad V. Gangal, PhD,c and
Balaram Ghosh, PhDa Delhi and Jaipur, India
From athe Center for Biochemical Technology, Mall Road, Delhi; bSMS
Medical College, Jaipur; cVallabhbhai Patel Chest Institute, Delhi Univer-
sity, Delhi; dBabu Jagjivan Ram Hospital, Jehangirpuri, Delhi; and eAll-
India Institute of Medical Sciences, Delhi.
Supported by the Council for Scientific and Industrial Research and the
Department of Biotechnology, Government of India. Mr Ram Nagarkatti
was granted a fellowship by University Grants Commission, Government
of India.
Received for publication February 22, 2002; revised May 13, 2002; accepted
for publication July 2, 2002.
Reprint requests: Balaram Ghosh, PhD, Molecular Immunogenetics Labora-
tory, Centre for Biochemical Technology, Mall Road, New Delhi-110007.
© 2002 Mosby, Inc. All rights reserved.
0091-6749/2002 $35.00 + 0 1/81/127859
doi:10.1067/mai.2002.127859
Abbreviations used
bp: Base pair[s]
HSD: Honestly significant difference
TsIgE: Total serum IgE
J ALLERGY CLIN IMMUNOL
VOLUME 110, NUMBER 3
Nagarkatti et al 411
A
st
hm
a,
 r
hi
ni
tis
,
ot
he
r 
re
sp
ir
at
or
y
di
se
as
es
sequenced (ABI-Prism 377 Automated Sequencer, PE Biosystems).
The CA-repeats were genotyped through use of Tet-labeled forward
primer and analyzed with internal standard ladder ABI-550
TAMRA on an ABI Prism 377 Sequencer through use of GeneScan
version 2.1 software.6 Products ranging from 198 bp to 214 bp were
obtained. Random samples of homozygous individuals (n = 10)
were sequenced to confirm the number of repeats.
We used the Kolmogorov-Smirnov test to look for differences
between allele size distributions in patients and control subjects and
the Mann-Whitney U test to look for differences between median
allele sizes. We used the Fisher exact test to look for differences
between patients and control subjects for selected alleles. To deter-
mine whether there was a significant difference between patients (n
= 90) and control subjects (n = 85) with respect to mean TsIgE lev-
els, a z test was performed. We tested for association between geno-
types and TsIgE value using 1-way ANOVA.
RESULTS 
We report the presence of 8 alleles—CA10 being novel,
with a heterozygosity index of 0.6953 and a polymorphic
information content of 0.6398—at the IFNG locus (Fig
1). We verified that the control group was consistent with
Hardy-Weinberg equilibrium conditions (χ2 = 3.16; df =
7; P > 0.75). The CA10 and CA11 alleles accounted for
approximately 28% of alleles in the patients, whereas
they represented less than 1% of those in the control sub-
jects. The Kolmogorov-Smirnov test showed a significant
difference between allele frequency distributions for the 2
groups (largest difference = 0.28; χ2 = 28.07; P < 10–6).
The Mann-Whitney U test showed a significant difference
between the median allele sizes for the 2 groups (U
=–7.16; P < 10–5). The results of the Fisher exact test for
repeat sizes 10 (difference of frequencies between the 2
groups = 0.13), 11 (0.16), 13 (0.10), and 15 (0.17) showed
all of them to be significantly different (P < 10–7, P <
10–8, P < .02 and P < 10–6, respectively). It thus appears
that alleles CA10 and CA11 are associated with asthma
whereas alleles CA13 and CA15 are more likely to occur
in normal individuals (Fig 1).
A significant difference (z = 6.62; P < .001) with
respect to mean TsIgE levels between patients (405 ±
465 IU/mL) and control subjects (254 ± 229 IU/mL) was
found through use of a z test. In addition, we found a sig-
nificant difference between mean TsIgE values for 8
genotypes in the control subjects (Table I; F = 6.35, df =
7.65; P = 1.07 × 10–5) using 1-way ANOVA.
The result of a post hoc Tukey test showed that the
mean IgE value for genotype (15,15) was significantly
different from those of genotypes (12,12), (12,13),
(13,13), (13,15) (honestly significant difference [HSD] =
295.52 IU/mL for P < .01), (13,14), and (12,15) (HSD =
248.28 IU/mL for P < .05). 
Similarly, for patients, 1-way ANOVA showed a sig-
nificant difference in TsIgE levels for different genotypes
(Table I; F = 2.88; df = 10.69; P = .0036). The result of a
post hoc Tukey test showed genotype (10,10), which had
the highest mean TsIgE value (891.41 IU/mL), to be sig-
nificantly different (HSD = 697.74 IU/mL for P < .05)
from genotypes (13,13) and (13,14). In general, the mean
TsIgE values decrease as allele size in the genotype
increases, except when an allele of size 15 is present
(Table I). Similar results were obtained when genotypes
with ≥3 observations were excluded from the ANOVA
(data not shown).
No polymorphism in the proximal promoter region
(–350 to +5 bp) was detected.
DISCUSSION
We report here a significant difference in the frequen-
cies of alleles between patients and with age/sex-
matched unrelated control subjects, suggesting that the
IFNG locus is associated with atopic asthma in the
Northern Indian population. Specifically, the CA10 and
CA11 alleles were found to be associated with asthmatic
individuals (Fig 1). Earlier studies in a Japanese popula-
tion reported an association of CA16 and CA18 alleles
with childhood atopic asthma but not with TsIgE levels7;
notably, the CA10 and CA11 alleles were not detected in
the study population. Inasmuch as the allelic distribution
in our population (8 alleles) was different from that in the
Japanese population (7 alleles), a direct correlation can-
not be made. Moreover, the criteria applied for proband
TABLE I. Mean IgE values for patients and control sub-
jects according to genotype
Mean IgE value (IU/mL)
Genotype* Control subjects Patients
1010 — 891.41 ±131.81 (9)
1011 — 521.98 ±197.72 (4)
1111 — 501.72 ± 119.23 (11)
1212 226.74 ± 48.26 (13) 406.46 ± 76.10 (27)
1213 118.62 ± 41.02 (18) 99.58 ± 161.44 (6)
1214 321.50 ± 100.47 (3) 96.67 ± 228.30 (3)
1215 314.90 ± 48.26 (13) 566.67 ± 228.30 (3)
1313 101.18 ± 58.00 (9) 77.48 ± 125.05 (10
1314 99.20 ± 123.05 (2) 65.00 ± 275.12 (2)
1315 251.32 ± 58.00 (9) 304.17 ± 228.30 (3)
1415 — 106.25 ± 275.12 (2)
1515 598.92 ± 71.04 (6) —
IgE values are given as means ± SEMs; numbers of individuals (n) are
given in parentheses.
*Genotypes observed in at least 2 individuals.
FIG 1. Comparison of patient and unrelated control groups with
respect to allelic distribution.
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selection, such as proband age (2.9 ± 3.3 years), and eth-
nic variation are possible explanations for the differences
observed between the studies. To minimize study errors
resulting from stratification, we selected individuals on
the basis of results of analysis of their pedigree, origin,
and migration status.
The IFNG CA-repeat polymorphism is likely to be
associated with atopic asthma, as already shown in other
TH1/TH2-mediated disorders (http://www.pam.bris.
ac.uk/services/GAI/cytokine4.htm),8 either directly or
through 1 or more functional polymorphisms in linkage
disequilibrium with it. It is known that IFN-γ plays a
direct role in downregulating IL-4–mediated IgE expres-
sion through signal transducer and activator of transcrip-
tion 1 and silencer of cytokine signaling 1 proteins.9 In
our study, genotypes containing CA10 and CA15 alleles
showed higher TsIgE levels (Table I). However, the rea-
son for this association is purely speculative at this time.
In a study conducted on healthy individuals, the presence
of the CA12 allele was correlated with higher levels of
IFN-γ production from PBMCs stimulated with PHA.6 In
another study, however, no such correlation was observed
when intracellular IFN-γ levels were measured through
use of flow cytometry.8 Therefore, further experiments,
such as DNA transfection, would be required to clarify
the role of the CA-repeat in IFNG gene expression.
Although various other polymorphisms in the promot-
er intronic regions and the 3′ UTR have been detected, no
functional correlation has been established.5,8,10 It is pos-
sible that the alleles CA10 and CA15 in our population are
linked to 1 or more as-yet-unidentified functional poly-
morphisms. Accordingly, identification of other poly-
morphisms, along with linkage disequilibrium analysis
and haplotype association, will be necessary for further
insight into these findings.
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